VEGFC and type 2 diabetes mellitus: • Dyslipidemia• Susceptibility to development of obesity-induced type 2 diabetes• Increased lymphatic collecting vessel permeability associated with reduced NO bioavailability• Decreased expression of VEGFR-3 at protein level• Exogenous VEGF-C administration improves wound healing and enhances lymphangiogenesis response• Abnormal lymphatic proliferation in renal cortex and medulla